BigHat Biosciences, Inc., a biotechnology company with a machine learning-guided antibody discovery and development platform, announced a collaboration with MSD (tradename of Merck & Co., Inc., Rahway, N.J., USA) to apply the company’s technology to design candidates for up to three drug discovery programs.